These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: a case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen. Pous A; Izquierdo C; Cucurull M; Sánchez S; Lezcano C; Domenech M; Llobera L; Plaja A; Moran T Transl Lung Cancer Res; 2021 Apr; 10(4):1917-1923. PubMed ID: 34012801 [TBL] [Abstract][Full Text] [Related]
5. How can we manage the cardiac toxicity of immune checkpoint inhibitors? Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484 [No Abstract] [Full Text] [Related]
6. Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Ohnishi T; Sagara H Curr Oncol; 2021 Feb; 28(2):1094-1113. PubMed ID: 33673470 [TBL] [Abstract][Full Text] [Related]
7. Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection. Alkrekshi A; Tamaskar I Oncologist; 2021 May; 26(5):e827-e830. PubMed ID: 33655663 [TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS. Chen C; Chen T; Liang J; Guo X; Xu J; Zheng Y; Guo Z; Chi L; Wei L; Chen X; Ye X; He J Front Pharmacol; 2021; 12():616505. PubMed ID: 33643048 [TBL] [Abstract][Full Text] [Related]